Histone deacetylase (HDAC) inhibitors prevent neural cell death in in vivo models of cerebral 26 ischaemia, brain injury and neurodegenerative disease. One mechanism by which HDAC 27 inhibitors may do this is by suppressing the excessive inflammatory response of chronically 28 activated microglia. However, the molecular mechanisms underlying this anti-inflammatory 29 effect and the specific HDAC responsible are not fully understood. Recent data from in vivo 30 rodent studies has shown that inhibition of class I HDACs suppresses neuroinflammation and 31 is neuroprotective. In our study we have identified that selective HDAC inhibition with 32 inhibitors apicidin, MS-275 or MI-192, or specific knockdown of HDAC1 or 2 using siRNA, 33 suppresses the expression of cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha 34 (TNF-in BV2 murine microglia activated with lipopolysaccharide (LPS). Furthermore, we 35 found that in the absence of HDAC1, HDAC2 is upregulated and these increased levels are 36 compensatory, suggesting these two HDACs have redundancy in regulating the inflammatory 37 response of microglia. Investigating the possible underlying anti-inflammatory mechanisms 38
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Significance Statement 43
The number of patients suffering a stroke or a neurodegenerative disease, such as Alzheimer's 44 is increasing These conditions are severely debilitating and are leading causes of mortality, 45 with neural cell death and loss of brain tissue being a major feature. A number of mechanisms 46 contribute to neuronal death, including inflammation in the brain, but we still lack clinical 47 therapies to inhibit this. The work presented here provides further insight into potential 48 molecular therapeutic targets called histone deacetylases (HDACs), which are thought to 49 contribute to neural cell death by promoting inflammation. We show that down regulation of 50 HDAC1 and 2 is sufficient to reduce this inflammatory response. Our findings have clinical 51 relevance because they identify HDAC1 and 2 as promising targets for therapy. 52 (Camelo et al., 2005; Zhang et al., 2010) . Therapies for treating 65 brain injury and disease are lacking, but these studies highlight a role for HDACs in 66 neuroinflammation and suggest they are appropriate targets to inhibit. 67
68
The mechanism by which HDAC inhibition is anti-inflammatory is not understood, but we 69 know HDACs remove acetyl groups from lysine residues on proteins including, histones 70 (Strahl and Allis, 2000) , enzymes and transcription factors (Glozak et al., 2005; Yao and Yang, 71 2011) . As a consequence, deacetylation of histones promotes a compact chromatin structure 72 and reduces gene expression, and deacetylation of specific lysine residues on transcription 73 factors can modulate their activity (Gu and Roeder, 1997; Boyes et al., 1998) . The identity of 74 which acetylated proteins are responsible for the anti-inflammatory responses observed when 75 using HDAC inhibitors is unclear. 76
77
There are 18 mammalian HDAC isoforms (class I HDACs (1, 2, 3 and 8), class II HDACs (4-78 7, 9 and 10), class III sirtuins (1-7) and the class IV HDAC11) and the majority of studies to 79 date have focused on using non-selective HDAC inhibitors such as suberoylanilide hydroxamic 80 acid (SAHA), trichostatin-A (TSA) and valproic acid (VPA) which inhibit the majority of these 81 isoforms. As a result, we do not know which HDACs modulate the microglial inflammatory 82 response and how inhibition of these leads to the acetylation of specific proteins to reduce 83 neuroinflammation. Recent studies have begun to address these questions and have shown that In our study, we have used selective HDAC inhibitors and siRNA mediated knockdown to 91 identify HDAC1 and HDAC2 as the key HDACs involved in the neuroinflammatory response 92 of microglia. We show that selective class I HDAC inhibitors and siRNA to specifically 93 knockdown HDAC1 and 2, both suppressed the expression of cytokines in BV2 murine 94 microglia. Knockdown of HDAC1 alone resulted in a compensatory increase in the levels of 95 HDAC2 and did not suppress cytokine expression, showing these two enzymes have 96 redundancy in the neuroinflammatory response. We show that the HDACi are effective in the 97 absence of new protein synthesis suggesting that the anti-inflammatory mechanism of HDACi 98 does not involve increased protein expression. This identification suggests that HDAC 99 selective inhibitors may be therapeutically useful for targeting microglia and 100 neuroinflammation, in brain injury and disease by modulating the acetylation levels and 101 function of non-histone protein(s). 102 in 100 L of Opti-MEM® and 1 L of 50 M siRNA was dissolved in 100 L of Opti-Mem®, 127 these were incubated for 5 minutes before combining and incubating for a further 20 minutes 128 at room temperature. Afterwards, 200 L of this mix was added to the well, followed by 129 incubation at 37°C in a humid atmosphere with 5% CO2 for 4 hours. This was then removed 130 and the cells were cultured in 3 mL DMEM high glucose AQmedia™ supplemented with 1% 131 v/v FBS and 100U penicillin/100 g streptomycin for 24 hours. Medium was then changed and 132 the cells were cultured for a further 24 hours before treating with 500 ng/mL LPS for 6 hours. 6 and TNF- mRNA expression was increased by 3384 ± 271% and 50990 ± 5190% 247 respectively ( Fig 1A) , and after 24 hours IL-6 protein secretion was increased by 5406 ± 439% 248 ( Fig 1F) . BV2 cells express the class I HDACs, 1, 2 and 3 with highest levels of HDAC1 and 249 lowest levels of HDAC3 (Fig 1B, C) . Treatment with the HDAC inhibitors, SAHA and VPA 250 produced an increase in the level of Histone H4 acetylation levels within 1 hr which was stable 251 over a period of 24 hr ( Fig 1D) suggesting these inhibitors provide rapid and stable HDAC 252 inhibition. Activation by LPS in the presence of either 1 M SAHA or 10 mM of VPA, 253 produced a significantly reduced response in IL-6 mRNA expression by 84.1 ± 2.8% (P = 254 0.004) and 89.7 ± 1.6%respectively and TNF- mRNA expression by 59.7 ± 3.2% and 77.9 ± 255 2.5% respectively ( Fig 1E) . Furthermore, SAHA significantly suppressed the LPS induced 256 increase in IL-6 protein secretion by 85.6 ± 2.5% ( Fig 1F) . 257
MATERIALS & METHODS

258
In order to understand the role of specific HDACs in microglia and neuroinflammation, we 259 tested HDAC inhibitors that show some selectivity towards specific HDAC isoforms in vitro. Although the HDAC inhibitors show selectivity, they are not isoform specific, therefore we 282 used an siRNA approach to specifically knockdown HDAC1 and HDAC2 to determine their 283 involvement in the inflammatory response of microglia. We were able to significantly knock-284 down HDAC1 protein expression by 62.6 ± 4.5% ( Fig 3A) and HDAC2 protein expression by 285 68.8 ± 7.7% ( Fig 3A) . Knockdown of HDAC1 resulted in an increased expression of HDAC2 286 with no change in HDAC3 ( Fig 3A) , while knockdown of HDAC2 did not result in any change 287 of expression of HDACs 1 or 3 ( Fig 3A) . Following knockdown, we treated cells to 500 ng/mL 288 LPS for 6 hours and assessed the expression of IL-6 and TNF-α mRNA. We found, that cells 289 in which HDAC1 was knocked down, there was no change in the response to LPS compared 290 to control cells (not shown) but cells in which HDAC2 was knocked down showed a reduced 291 induction of IL-6 (by 48.2 ± 13%) and TNF- (by 22.0 ± 3.6%) expression in response to LPS 292 ( Fig 3B) . To determine if the increase in HDAC2 expression, as a result of HDAC1 293 knockdown, was acting as a compensatory mechanism we used HDAC1 siRNA to knockdown 294 HDAC1 in combination with a titrated amount of HDAC2 siRNA to reduce HDAC2 to levels 295 seen in control cells (Fig. 3, HDAC1 + 2) . Using this approach we were able to significantly 296 reduce HDAC1 levels by 63.5 ± 2.4%, while maintaining the level of HDAC2 to that seen in 297 control cells (89.7 ± 6.2%, Fig 3A HDAC1 + 2) . The expression of HDAC3 was not 298 significantly altered (116 ± 5% of Scr siRNA). Cells in which HDAC1 levels are reduced but 299 HDAC2 levels are unchanged showed a reduced response to LPS with with IL-6 and TNF-α 300 mRNA levels of 34.8 ± 3.0% and 35.7 ± 4.8% respectively compared with control cells (Fig  301   3B ). 302
In summary our data identify HDAC1 and 2 activities as important contributors to the 303 neuroinflammatory response of microglia. Furthermore, they show redundancy in this function 304 with increased HDAC2 levels being compensatory for reduced HDAC1. The mechanism by which HDAC inhibitors exert their effects is often assumed to involve 310 increase in gene expressionindeed HDAC inhibitors do result in increased histone acetylation 311 (e.g. Fig 1D) suggesting that acetylation is involved in many more processes than gene regulation alone. To 316 determine if the anti-inflammatory action of HDAC inhibition results from changes in gene 317 expression we blocked new protein synthesis using cycloheximide and tested the effectiveness 318 of HDAC inhibitors to block IL-6 and TNF-α stimulation by LPS. Incubation of BV2 cells with 319 cycloheximde for 1 or 3 hours completely blocked new protein synthesis as measured by O-320 propargyl-puromycin incorporation and protein synthesis was blocked under all conditions 321 used to quantify gene expression levels ( Fig 4A) . Continued exposure to cycloheximide for 6 322 hr led to cell death (not shown) though cells were still healthy after 3 hour exposure. The 323 presence of cycloheximde did not affect the induction of IL-6 mRNA expression by LPS (Fig  324   4B , compare left two bars) and did not prevent either SAHA or apicidin inhibiting this response 325 ( Fig 4B, right two bars) . Thus these data indicate that the mechanism by which HDAC 326 inhibition reduces the inflammatory response in microglia is manifest within 3 hours and does 327 not require new protein synthesis. Together this suggests that increased gene expression 328 resulting from enhanced histone acetylation is not important for ability of HDAC inhibitors to 329 reduce microglia activation and future work should am to identify the important molecular Chuang, 2014). However, the identity of the important HDACs involved has not been 338 uncovered and the mechanism by which HDAC inhibition is beneficial is yet to be elucidated. 339
Here we have shown that the function of both HDAC1 and HDAC2 contribute to the 340 inflammatory response in microglia and that in the absence of HDAC1, increased HDAC2 341 levels compensate suggesting that these two HDACs show redundancy in this function. 342
Furthermore the effectiveness of HDAC inhibition in the absence of new protein synthesis 343 suggests that the HDACs are promoting the inflammatory response by regulating the 344 acetylation levels of a non-histone protein rather than increasing levels of gene expression as a 345 result of increased histone acetylation. 346
347
Microglia are often referred to as the immune cells of the brain and recently, selective inhibition 348 and genetic knockdown of class I HDACs, was shown to reduce the production of cytokines in 349 the inflammatory response of macrophages (Jeong et al., 2014) . In macrophages, knockdown 350 of either HDAC1 or 2 resulted in increased expression of the other and only a combined 351 knockdown of HDACs 1, 2 and 3 resulted in reduced inflammatory response to LPS (Jeong et 352 al., 2014) . In T-lymphocytes deletion of HDAC1 resulted in an increase in HDAC2 protein 353 levels but deletion of HDAC2 had no effect on HDAC1 (Dovey et al., 2013) . Here we show 354 that in microglial cells, HDAC1 is the most highly expressed class I HDAC and knockdown 355 of HDAC1 resulted in a compensatory increase in the levels of HDAC2 ( Fig 3A) . Likewise, 356 we did not observe any compensatory increase in the levels of HDAC1 protein upon 357 knockdown of HDAC2 ( Fig 3A) however this contrasts to observations made using 358 macrophages (Jeong et al., 2014) . The mechanisms resulting in a compensatory increase in one 359 HDAC upon loss of another are not known though HDAC1 does regulate its own promoter 360 (Schuettengruber et al., 2003) and may also repress expression of other HDACs. One prediction 361 of such a model would be that chemical inhibition of HDAC activity would also result in such 362 compensatory increase. However, we did not observe any compensatory changes in HDAC 363 expression in cells treated with HDAC inhibitors (not shown), suggesting it is not brought about 364 by loss of HDAC enzyme activity but is potentially a mechanism involving the absence of the 365 protein itself. In the absence of HDAC1 in T-lymophocytes the levels of SIN3 and MTA2 are 366 reduced which may indicate that incomplete co-repressor complexes are turned over quickly 367 (Dovey et al., 2013) . This structural, rather than enzymatic, requirement for HDAC1 may 368 underlie the reason that knockdown of HDAC1, but not inhibition results in a compensatory 369 increase in HDAC2. Additionally, compensatory changes in HDAC protein levels have been 370 observed in the absence of changes in mRNA levels, suggesting the mechanism involves 371 enhanced translation or protein stability (Jurkin et al., 2011) . 372 373 HDAC1 and 2 do not exist in the cell as isolated enzymes but are components of three 374 independent co-repressor complexes; Sin3, NuRD and CoREST (for a review see (Kelly and 375 Cowley, 2013) ). Each co-repressor complex contains two molecules of HDAC which may 376 consist of two molecules of HDAC1, two molecules of HDAC2 or one of each. Others have 377 observed that upon a loss of HDAC1, HDAC2 can become incorporated into the Sin3, NuRD 378 and CoREST multi-protein complexes in its place (Dovey et al., 2013) . The compensatory 379 effect of HDAC2 in the inflammatory response may be explained by such a mechanism. 380 Following a loss of HDAC1, HDAC2 is upregulated and this HDAC is incorporated into a 381 specific complex in place of HDAC1. This complex, specifically targets a protein (which 382 regulates the inflammatory response) for deacetylation. Regardless of the HDAC composition, 383 be it two molecules of HDAC1, HDAC2 or one of each, the specificity for the substrate to be 384 deacetylated comes from the complex itself rather than the HDACs. This hypothesis would 385 suggest it doesn't matter which of the two HDAC isoforms is inhibited, an anti-inflammatory 386 effect depends on a reduction in the number and activity of this specific functional multi-387 protein complex. Similarly, the compensatory effect of HDAC3 when HDAC1 and 2 are both 388 lost in macrophages (Jeong et al., 2014 ) may be explained by HDAC3 being in a specific 389 complex that targets the same substrate as the complex with either HDAC1 or 2. Further 390 research is now needed to investigate these hypotheses and identify the complexes (and 391 composition of them) that when inhibited is responsible for the suppression of pro-392 inflammatory mediator expression in BV2 microglia. 393
394
What is the important target of HDAC1 and 2 that promotes the inflammatory response? Our 395 data identify that new protein synthesis is not required for the HDAC inhibitor response. 396
Formally, we cannot rule out a transcriptional response involving increased miRNA expression 397 and subsequent down regulation of a protein targeted by the miRNA(s), however the ability of 398 the inhibitors to show effectiveness within 3 hours makes such a mechanism unlikely. HDAC 399 enzymes were originally characterised by their ability to deacetylate histone proteins, however 400 these are not their only target and the acetylome may contain on the order of 4000 proteins 401 (Choudhary et al., 2009; Liu et al., 2014) . Additionally, the original idea, that HDAC inhibition 402 leads to increased histone acetylation and increased gene expression is likely too simplistic 403 because as many genes are repressed as are activated upon HDAC inhibition by SAHA (Peart 404 et al., 2005) . The specific HDAC target(s) important for the microglial response has not been 405 unequivocally identified though a number of potential target proteins can be implicated based 406 on a correlation of their acetylation with microglial activation. Perhaps the most studied non-407 histone protein involved in the inflammatory response and regulated by acetylation is the 408 transcription factor NF-κB . Quiescent NF-κB is restricted to the 409 cytoplasm via its inhibitory binding partner IκB but upon cell stimulation becomes dissociated 410 and moves into the nucleus where it activates target gene expression. Initially, it was proposed 411 that deacetylation of NF-κB enhanced its interaction with IκB and removal from the nucleus 412 however NF-κB can be acetylated at multiple sites and more recent data suggests that 413 deacetylation at specific residues can result in activation of a subset of NF-κB targets 414 (Rothgiesser et al., 2010) , thus inhibition of HDACs may enhance the level of acetylated NF-415 κB, reducing its activity. In support of this idea, Furumai et al, 2011 showed that inhibition of 416 HDACs in HeLa cells, with TSA, caused a reduction in the recruitment of NF-κB, and RNA 417 polymerase II to the promoter of IL-8, which in turn caused a reduction in IL-8 expression 418 (Furumai et al., 2011) . Another candidate protein is MKP-1, a member of the MAPK 419 inflammatory signalling pathway and negative regulator of the inflammatory response. In 420 macrophages MKP-1 activity is reduced when it is deacetylated by HDAC1, 2 or 3 (Jeong et  421 al., 2014). MKP-1 is not just expressed in macrophages but also in microglia (Eljaschewitsch 422 et al., 2006) making this another attractive candidate for the functional response observed here. 423
424
In summary our new data here highlight a role for HDAC1 and 2 in regulating microglia 425 activation and suggest the mechanism by which they do so involves acetylation of proteins 426 other than histones. Future studies should now be aimed toward identifying which proteins are 427 the important targets. Although HDAC inhibitors have been approved clinically in the 428 treatment of some cancers they are not without side effects and a more complete understanding 429 of their mechanism of action would open doors to more specific therapeutic targets. 
